Effects of imipenem-cilastatin sodium combined with immunoglobulin on serum PCT, hs-CRP and TNF-α in children with baby sepsis complicated with disseminated intravascular coagulation

doi:10.12092/j.issn.1009-2501.2020.05.013

Abstract

Abstract: AIM: To investigate the effects of imipenem-cilastatin sodium combined with immunoglobulin on serum PCT, hs-CRP and TNF-α in child with baby sepsis complicated with disseminated intravascular coagulation (DIC). METHODS: Ninty-two cases of patients with sepsis and DIC neonates admitted to our hospital from January 2013 to April 2019 were enrolled in this study. All the children were divided into observation group and control group according to random number table method, 46 cases in each group. The patients in the control group were treated with imipenem-cilastatin sodium, and the patients in the observation group were treated with imipenem-cilastatin sodium combined with immunoglobulin. The efficacy of the two groups, the time of DIC index returned to normal, bleeding stopped and ICU hospitalization time, coagulation parameters (FIB, PLT, D-D, TT), serum inflammatory factor levels and incidence of adverse reactions were compared. RESULTS: The total effective rate of treatment in the observation group was 93.48% (43/46), which was higher than that in the control group (78.26%, 36/46) (P<0.05). The DIC index of the observation group returned to normal time, bleeding stop time, ICU hospitalization time was shorter than those of the control group (P<0.05). After 5 days of treatment, the plasma levels of FIB, D-D and TT were decreased in the two groups, and the observation group was lower than those of the control group, the difference was statistically significant (P<0.05). After 5 days of treatment, the expressions of serum PCT, hs-CRP and TNF-α were decreased in the two groups, and the observation group was lower than the control group (P<0.05). There was no significant difference in the incidence of adverse drug reactions between the two groups [2.17% (1/46) vs. 6.52% (3/46)] (P>0.05). CONCLUSION: Imipenem-cilastatin combined with immunoglobulin is effective in the treatment of baby sepsis complicated with DIC. It can alleviate or eliminate bleeding and other symptoms, shorten ICU hospitalization time, improve coagulation function, and reduce serum PCT and hs-CRP, TNF-α expression, and the body's inflammatory response, combined with fewer adverse reactions, which has a higher clinical value.

Key words: imipenem-cilastatin sodium, immunoglobulin, baby sepsis, disseminated intravascular coagulation, serum inflammatory factor

CLC Number:

R631
R72

RU Caiwang, YUAN Tianming, YANG Bingfen, WU Fugen, LIN Yingrong, MO Miaojun. Effects of imipenem-cilastatin sodium combined with immunoglobulin on serum PCT, hs-CRP and TNF-α in children with baby sepsis complicated with disseminated intravascular coagulation[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 559-565.

References

[1]何源, 易海英, 杨树杰, 等. 肺炎合并脓毒症患儿外周血调节性T细胞含量与炎症应激反应、免疫应答的相关性研究 [J]. 海南医学院学报, 2018, 24(4): 530-533.
[2]张升荣, 李晓东, 田青, 等. 低分子肝素治疗新生儿脓毒症并DIC的临床研究 [J]. 实用中西医结合临床, 2016, 16(9): 14-16.
[3]Varljen T, Rakic O, Sekulovic G, et al. Association between tumor necrosis factor-α promoter-308 G/A polymorphism and early onset sepsis in preterm infants [J]. Tohoku J Exp Medicine, 2019, 247(4): 259-264.
[4]涂厉标, 计建军, 王长江, 等. 免疫球蛋白静脉注射辅助治疗新生儿脓毒症的临床疗效 [J]. 浙江临床医学, 2017, 19(10): 1857-1859.
[5]张琪, 费雅楠, 姜利. ICU脓毒症合并急性肾损伤患者CRRT后死亡?危险因素:一项多中心观察研究数据的二次分析 [J]. 中华危重病急救医学, 2019, 31(2): 155-159.
[6]谢辉, 张震环, 邢娟. 降钙素原和血乳酸对脓毒症合并弥散性血管内凝血的诊断价值 [J]. 微循环学杂志, 2016, 26(2): 21-23, 30.
[7]王卓, 王学宽, 陈强, 等. 联合检测PCT、hs-CRP在新生儿脓毒症诊疗中的应用价值 [J]. 中国微生态学杂志, 2017, 29(9): 1049-1051.
[8]刘炳炜, 胡炜, 胡伟航, 等. TNF-α、Pro-BNP在脓毒症心功能障碍中的作用 [J].中华全科医学, 2017, 15(10): 1678-1680, 1811.
[9]周红瑜, 盖磊, 颜碧清, 等. 低分子肝素对ICU脓毒症患者ALI/ARDS氧合指数及炎症反应的影响观察 [J]. 中国药师, 2019, 22(1): 106-108.
[10]Joshi P, Shah B, Joshi V, et al. Treatment of elizabethkingia meningoseptica baby meningitis with combination systemic and intraventricular therapy [J]. Ind J Pedia, 2019, 86(4): 379-381.
[11]冼丽娜, 杨远征, 孙广晓, 等. 降钙素原、超敏C反应蛋白及D-二聚体在脓毒症所致急性呼吸窘迫综合征中的诊断和预后评估价值 [J]. 中国医药导报, 2018, 15(22): 74-76, 84.
[12]石晓娜, 徐梅先, 孙素真, 等. 不同剂量血液滤过治疗小儿脓毒症休克的效果及对安全性的影响 [J]. 河北医科大学学报, 2019, 40(4): 488-491.
[13]杜晓敏. 加味防己茯苓汤联合CRRT疗法对脓毒症急性肾损伤患者肾功能及血清APN、PCT、Lac水平变化的影响 [J]. 中国医药导刊, 2019, 21(3): 152-156.
[14]袁文浩, 曾凌空, 蔡保欢, 等. 血流动力学监测预测新生儿脓毒症休克液体复苏反应性的价值 [J]. 中华新生儿科杂志(中英文), 2019, 34(2): 103-108.
[15]Kumar J, Singh A. A comparative evaluation of presepsin with procalcitonin and crp in diagnosing baby sepsis: correspondence [J]. Ind J Pedia, 2019, 86(3): 313-314.
[16]付慧. 丹参川芎嗪注射液对脓毒症患儿外周血前白蛋白、降钙素原、肿瘤坏死因子-α及T细胞亚群的影响 [J]. 中国临床医生杂志, 2018, 46(1): 100-103.
[17]朱丽丽, 师东武. 中性粒细胞明胶酶相关脂质运载蛋白联合白细胞介素-18在脓毒症急性肾损伤患者早期启动连续性肾脏替代治疗中的预测价值 [J]. 中国药物与临床, 2019, 19(6): 874-877.
[18]Rose MA, Townsend JP, Calvert J, et al. Increased surfactant protein-D levels in the airways of preterm neonates with sepsis indicated responses to infectious challenges [J]. Acta Paediatrica, 2019, 108(5): 870-876.
[19]易林高, 陈晓孩, 何国鑫, 等. 头孢哌酮舒巴坦在重症监护病房脓毒症患者体内的药代动力学研究 [J]. 中国医药导报, 2018, 15(10): 34-37, 41.
[20]郭宗尚. 脓毒症前DIC期患者应用低剂量肝素治疗的临床观察及其对预后的影响 [J]. 临床医药实践, 2019, 28(3): 172-174.
[21]杨勇, 彭友林, 黄凯, 等. 乌司他丁辅助治疗对脓毒症患者炎症细胞亚群及分泌细胞因子的影响 [J]. 现代中西医结合杂志, 2019, 28(4): 427-430.
[22]卢艳辉, 刘振奎, 李世阳, 等. 血清学指标联合小儿危重病例评分和Brighton儿童早期预警评分预测脓毒症患儿死亡的巢式病例对照研究 [J]. 中国全科医学, 2019, 22(15): 1800-1806.